• Explore /
  • Poster
  • / ATNEC: A multicenter, randomized trial investigating whether axillary treatment can be avoided in patients with T1-3N1M0 breast cancer with no residual cancer in the lymph glands after neoadjuvant chemotherapy.

ATNEC: A multicenter, randomized trial investigating whether axillary treatment can be avoided in patients with T1-3N1M0 breast cancer with no residual cancer in the lymph glands after neoadjuvant chemotherapy.

Abstract Poster

Authors

Amit Goyal

Amit Goyal

Royal Derby Hospital, Derby, United Kingdom

Amit Goyal , Sophie Cramp , Andrea Marshall , Natalie Hammonds , Duncan Wheatley , Beatrix Elsberger , Shama Puri , Tara Homer , Luke Vale , Roeum Butt , Zohal Nabi , Janice Rose , Helen Teresa Edwards , Samreen Ahmed , Abeer Shaaban , Julie Bruce , Sophie Gasson , Helen Higgins , Janet Dunn

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Local-Regional Therapy

Clinical Trial Registration Number

NCT04109079

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS615)

DOI

10.1200/JCO.2022.40.16_suppl.TPS615

Abstract #

TPS615

Poster Bd #

382a

Abstract Disclosures

Similar Posters

First Author: Amit Goyal

First Author: Rikiya Nakamura

First Author: Roberto Antonio Leon-Ferre

First Author: Amit Goyal